Neurocrine Biosciences Inc. (NASDAQ:NBIX) went up by 1.35% from its latest closing price compared to the recent 1-year high of $136.26. The company’s stock price has collected -1.42% of loss in the last five trading sessions. Press Release reported on 09/28/20 that Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS(R) (opicapone) in Patients with Parkinson’s Disease at the American Neurological Association 2020 Virtual Meeting
Is It Worth Investing in Neurocrine Biosciences Inc. (NASDAQ :NBIX) Right Now?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) scored a price-to-earnings ratio above its average ratio, recording 46.28 x from its present earnings ratio. Plus, the 36-month beta value for NBIX is at 1.23. Opinions of the stock are interesting as 15 analysts out of 25 who provided ratings for Neurocrine Biosciences Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 9 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $140.29, which is $42.83 above the current price. NBIX currently public float of 90.04M and currently shorts hold a 6.30% ratio of that float. Today, the average trading volume of NBIX was 764.92K shares.
NBIX’s Market Performance
NBIX stocks went down by -1.42% for the week, with a monthly drop of -15.81% and a quarterly performance of -22.26%, while its annual performance rate touched 11.04%. The volatility ratio for the week stands at 2.84% while the volatility levels for the past 30 days are set at 4.01% for Neurocrine Biosciences Inc.. The simple moving average for the period of the last 20 days is -5.34% for NBIX stocks with a simple moving average of -9.84% for the last 200 days.
Analysts’ Opinion of NBIX
JP Morgan, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $136. The rating they have provided for NBIX stocks is “Neutral” according to the report published on August 04th, 2020.
Goldman gave a rating of “Neutral” to NBIX, setting the target price at $135 in the report published on June 29th of the current year.
NBIX Trading at -12.72% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.48% of loss for the given period.
Volatility was left at 4.01%, however, over the last 30 days, the volatility rate increased by 2.84%, as shares sank -15.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.27% lower at present.
During the last 5 trading sessions, NBIX fell by -1.42%, which changed the moving average for the period of 200-days by -10.41% in comparison to the 20-day moving average, which settled at $102.03. In addition, Neurocrine Biosciences Inc. saw -9.33% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NBIX starting from ROBERTS EIRY, who sale 2,257 shares at the price of $118.84 back on Aug 05. After this action, ROBERTS EIRY now owns 11,446 shares of Neurocrine Biosciences Inc., valued at $268,225 using the latest closing price.
Lloyd-Smith Malcolm, the Chief Regulatory Officer of Neurocrine Biosciences Inc., sale 2,257 shares at $118.86 during a trade that took place back on Aug 05, which means that Lloyd-Smith Malcolm is holding 26,971 shares at $268,277 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- +28.75 for the present operating margin
- +98.11 for the gross margin
The net margin for Neurocrine Biosciences Inc. stands at +4.70. The total capital return value is set at 22.54, while invested capital returns managed to touch 4.65. Equity return is now at value 29.90, with 15.30 for asset returns.
Based on Neurocrine Biosciences Inc. (NBIX), the company’s capital structure generated 79.11 points at debt to equity in total, while total debt to capital is 44.17. Total debt to assets is 38.58, with long-term debt to equity ratio resting at 13.62. Finally, the long-term debt to capital ratio is 7.61.
Currently, EBITDA for the company is 124.70M with total debt to EBITDA at 1.75. When we switch over and look at the enterprise to sales, we see a ratio of 12.85, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 8.62 and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.